Alterations in sphingolipid metabolic gene expression B3GNT5 and GAL3ST1 were also identified in patients with NSCLC that reflected into the serum levels of their metabolites lacto/neolacto-series glycosphingolipids and sulfatides, implying their potential roles as biomarkers for NSCLC [31]. Here, GAL3ST1 is linked to non-small cell lung carcinoma.